Don't forget to take into account an anticipated $3 mill ATO R&D refund and a further $1.3 mill from conversion of partly paid shares so no need for additional capital for the next 12 months at which point MEB are hopefully on the brink of commercialism so any additional capital requirements could be on a much higher SP multiple. Potentially groundbreaking technology that won't go unnoticed by the investment community looking for the next disruption in mental health innovation.
